Catherine A. Schnabel

4.2k citations

103 papers · 2.8k indexed · h-index 26

Cancer Research top 1%
Molecular Biology top 10%
Oncology top 2%
Genetics top 5%
Pulmonary and Respiratory Medicine top 5%

Co-authors: Michael L. Cleary Yakop Jacobs Mark G. Erlander Dennis C. Sgroi Brock E. Schroeder Mitch Dowsett Ivana Šestak Jack Cuzick
Topics: Breast Cancer Treatment Studies (41 papers)Advanced Breast Cancer Therapies (30 papers)Estrogen and related hormone effects (26 papers)
Cited by: Cancer Research Oncology Genetics
Journals: Proceedings of the National Academy of Sciences Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: United States United Kingdom Canada

In The Last Decade

Catherine A. Schnabel

97 papers receiving 2.8k citations

Peers

Countries citing papers authored by Catherine A. Schnabel

Since Specialization

Citations

This map shows the geographic impact of Catherine A. Schnabel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine A. Schnabel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine A. Schnabel more than expected).

Fields of papers citing papers by Catherine A. Schnabel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine A. Schnabel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine A. Schnabel. The network helps show where Catherine A. Schnabel may publish in the future.

Co-authorship network of co-authors of Catherine A. Schnabel

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine A. Schnabel. A scholar is included among the top collaborators of Catherine A. Schnabel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine A. Schnabel. Catherine A. Schnabel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial 2024 ·Clinical Cancer Research ·Eleftherios P. Mamounas,Hanna Bandos,Priya Rastogi,(unknown),Kai Treuner,Peter C. Lucas,Charles E. Geyer,Louis Fehrenbacher,Stephen Chia,Adam Brufsky,Janice M. Walshe,Gamini S. Soori,Shaker R. Dakhil,Soonmyung Paik,Sandra M. Swain,Dennis C. Sgroi,Catherine A. Schnabel,Norman Wolmark	7
2	Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer 2023 ·BMC Cancer ·Julia Foldi,Anastasia Tsagianni,Max Salganik,Catherine A. Schnabel,Adam Brufsky,G. J. van Londen,Lajos Pusztai,Tara Sanft	4
3	LBA100 CUP-ONE trial: A prospective double-blind validation of molecular classifiers in the diagnosis of cancer of unknown primary and clinical outcomes 2023 ·Annals of Oncology ·Harpreet Wasan,Jiazhao Wang,Elaine McCartney,Harris S. Soifer,Kai Treuner,(unknown),Catherine A. Schnabel,Karen Carty,Lynn McMahon,T.R. Jeffry Evans,M. Nicolson,Helene Thygesen,(unknown),Karin A. Oien	2
4	Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study 2022 ·Clinical Cancer Research ·John M.S. Bartlett,Dennis C. Sgroi,Kai Treuner,Yi Zhang,Tammy Piper,Ranelle Salunga,Ikhlaaq Ahmed,Lucy Doos,(unknown),Karen J. Taylor,Elena F. Brachtel,Sarah Pirrie,Catherine A. Schnabel,Daniel Rea	25
5	Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study 2022 ·Breast Cancer Research ·Dennis C. Sgroi,Kai Treuner,Yi Zhang,Tammy Piper,Ranelle Salunga,Ikhlaaq Ahmed,Lucy Doos,(unknown),Karen J. Taylor,Elena F. Brachtel,Sarah Pirrie,Catherine A. Schnabel,Daniel Rea,John M.S. Bartlett	5
6	Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma 2021 ·Clinical Cancer Research ·Raquel Nunes,Tal Sella,Kai Treuner,Jennifer M. Atkinson,(unknown),Yi Zhang,Pedro Exman,David J. Dabbs,Andrea L. Richardson,Catherine A. Schnabel,Dennis C. Sgroi,Steffi Oesterreich,Ashley Cimino‐Mathews,Otto Metzger	13
7	7P An optimized Breast Cancer Index node-positive (BCIN+) prognostic model for late distant recurrence in patients with hormone receptor-positive (HR+) node-positive breast cancer 2021 ·Annals of Oncology ·Gerrit‐Jan Liefers,Iris Noordhoek,(unknown),Dennis C. Sgroi,Hein Putter,Kai Treuner,Jacqueline Wong,Elma Meershoek‐Klein Kranenbarg,Marjolijn Duijm‐de Carpentier,CJH van de Velde,Catherine A. Schnabel	2
8	11P A Breast Cancer Index (BCI) prognostic model for N0 HR+ breast cancer optimized for late distant recurrence 2021 ·Annals of Oncology ·John M.S. Bartlett,(unknown),Ikhlaaq Ahmed,Kai Treuner,Tammy Piper,Sarah Pirrie,Adam Brufsky,Dennis C. Sgroi,Catherine A. Schnabel,Daniel Rea	1
9	Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy 2020 ·Clinical Cancer Research ·Iris Noordhoek,Kai Treuner,Hein Putter,Yi Zhang,(unknown),Elma Meershoek‐Klein Kranenbarg,Marjolijn Duijm‐de Carpentier,Cornelis J.�H. van de Velde,Catherine A. Schnabel,Gerrit‐Jan Liefers	73
10	Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study 2020 ·Journal of Clinical Oncology ·Richard Buus,Ivana Šestak,Ralf Kronenwett,Sean Ferree,Catherine A. Schnabel,Frederick L. Baehner,Elizabeth A. Mallon,Jack Cuzick,Mitch Dowsett	62
11	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer 2018 ·JAMA Oncology ·Ivana Šestak,Richard Buus,Jack Cuzick,Peter Dubsky,Ralf Kronenwett,Carsten Denkert,Sean Ferree,Dennis C. Sgroi,Catherine A. Schnabel,Frederick L. Baehner,Elizabeth Mallon,Mitch Dowsett	204
12	A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes 2017 ·Clinical Cancer Research ·Yi Zhang,Brock E. Schroeder,Piiha-Lotta Jerevall,Amy Ly,(unknown),Catherine A. Schnabel,Dennis C. Sgroi	34
13	Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14 2016 ·Breast Cancer Research and Treatment ·Judith‐Anne W. Chapman,Dennis C. Sgroi,Paul E. Goss,(unknown),(unknown),Yi Zhang,Catherine A. Schnabel,Mark G. Erlander,Kathleen I. Pritchard,Lei Han,Tanja Badovinac-Črnjević,Lois E. Shepherd,Michaël Pollak	0
14	Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence 2013 ·Clinical Cancer Research ·Yi Zhang,Catherine A. Schnabel,Brock E. Schroeder,Piiha-Lotta Jerevall,Rachel C. Jankowitz,Tommy� Fornander,Olle Stål,Adam Brufsky,Dennis C. Sgroi,Mark G. Erlander	163
15	Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker 2013 ·JNCI Journal of the National Cancer Institute ·Dennis C. Sgroi,Erin Carney,Elizabeth Zarrella,(unknown),(unknown),Dianne M. Finkelstein,Jackie Szymonifka,Atul K. Bhan,Lois E. Shepherd,Yi Zhang,Catherine A. Schnabel,Mark G. Erlander,James N. Ingle,Peggy L. Porter,Hyman B. Muss,(unknown),Dongsheng Tu,David L. Rimm,Paul E. Goss	153
16	Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier 2012 ·Clinical Cancer Research ·Sarah E. Kerr,Catherine A. Schnabel,Peggy Sullivan,Yi Zhang,Veena Singh,(unknown),Mark G. Erlander,W. Edward Highsmith,Sarah Dry,Elena F. Brachtel	66
17	Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumors 2012 ·Expert Opinion on Medical Diagnostics ·Catherine A. Schnabel,Mark G. Erlander	6
18	Blinded Comparator Study of Immunohistochemical Analysis versus a 92-Gene Cancer Classifier in the Diagnosis of the Primary Site in Metastatic Tumors 2012 ·Journal of Molecular Diagnostics ·Lawrence M. Weiss,Peiguo Chu,Brock E. Schroeder,Veena Singh,Yi Zhang,Mark G. Erlander,Catherine A. Schnabel	54
19	Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes 2006 ·SHILAP Revista de lepidopterología ·Catherine A. Schnabel,Matthew Wintle,Orville Kolterman	1
20	CREB Binding Protein Interacts with Nucleoporin-Specific FG Repeats That Activate Transcription and Mediate NUP98-HOXA9 Oncogenicity 1999 ·Molecular and Cellular Biology ·Lawryn H. Kasper,Paul K. Brindle,Catherine A. Schnabel,Colin E.J. Pritchard,Michael L. Cleary,Jan M. A. van Deursen	271

About Catherine A. Schnabel

Catherine A. Schnabel is a scholar working on Cancer Research, Oncology and Genetics, having authored 103 papers that have together received 2.8k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (41 papers), Advanced Breast Cancer Therapies (30 papers) and Estrogen and related hormone effects (26 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (1.1k citations) and Genetics (640 citations). Catherine A. Schnabel has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Michael L. Cleary, Yakop Jacobs, Mark G. Erlander, Dennis C. Sgroi, Brock E. Schroeder, Mitch Dowsett, Ivana Šestak, Jack Cuzick, Colin E.J. Pritchard and Paul K. Brindle. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact